EGFR and head and neck squamous cell carcinoma: The first human phase I/IIa multicenter study of NIR-PIT with a cetuximab-IR700 conjugate (cetuximab sarotalocan sodium; RM1929) targeting epidermal growth factor receptor (EGFR) in patients with unresectable head and neck squamous cell carcinoma (HNSCC) was completed in 2017 [19]; with a “fast-tracked” global phase 3 clinical trial opening in 2019 and scheduled to be completed in 2024 (https://clinicaltrials.gov/ct2/show/NCT03769506, accessed on 12 October 2022).